Loading...
XNASBLUE
Market cap81mUSD
Jan 17, Last price  
8.35USD
1D
1.09%
1Q
1,601.30%
Jan 2017
-86.47%
IPO
-68.00%
Name

bluebird bio Inc

Chart & Performance

D1W1MN
XNAS:BLUE chart
P/E
—
P/S
2.75
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
16.11%
Rev. gr., 5y
-11.58%
Revenues
29m
+720.04%
882,000340,00020,181,00025,421,00014,079,0006,155,00035,427,00054,579,00044,674,000250,734,0003,662,0003,597,00029,497,000
Net income
-212m
L-20.51%
-15,598,000-23,670,000-25,321,000-48,709,000-166,783,000-263,507,000-335,643,000-555,625,000-789,608,000-618,695,000-562,638,000-266,578,000-211,913,000
CFO
-235m
L-33.41%
-12,217,000-21,044,00043,450,000-59,693,000-98,429,000-189,647,000-280,553,000-413,426,000-564,384,000-470,351,000-635,639,000-352,953,000-235,046,000
Earnings
Mar 24, 2025

Profile

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
URL
https://www.bluebirdbio.com/
IPO date
Jun 19, 2013
Employees
323
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
29,497
720.04%
3,597
-1.77%
Cost of revenue
201,179
250,841
Unusual Expense (Income)
NOPBT
(171,682)
(247,244)
NOPBT Margin
Operating Taxes
(126)
117
Tax Rate
NOPAT
(171,556)
(247,361)
Net income
(211,913)
-20.51%
(266,578)
-52.62%
Dividends
Dividend yield
Proceeds from repurchase of equity
248,198
54,237
BB yield
-163.76%
-9.97%
Debt
Debt current
105,907
51,160
Long-term debt
554,745
511,620
Deferred revenue
Other long-term liabilities
92
92
Net debt
438,897
379,625
Cash flow
Cash from operating activities
(235,046)
(352,953)
CAPEX
(4,189)
(13,208)
Cash from investing activities
154,950
250,453
Cash from financing activities
196,248
54,253
FCF
(147,247)
(437,481)
Balance
Cash
221,755
181,741
Long term investments
1,414
Excess cash
220,280
182,975
Stockholders' equity
(4,260,219)
(3,989,743)
Invested Capital
4,785,174
4,467,568
ROIC
ROCE
EV
Common stock shares outstanding
109,825
78,585
Price
1.38
-80.06%
6.92
-30.73%
Market cap
151,558
-72.13%
543,808
-21.01%
EV
590,456
923,433
EBITDA
(143,157)
(242,243)
EV/EBITDA
Interest
16,353
20,631
Interest/NOPBT